-
公开(公告)号:US20210069219A1
公开(公告)日:2021-03-11
申请号:US17082102
申请日:2020-10-28
Applicant: Pfizer Inc.
Inventor: Joseph Walter Strohbach , Tsutomu Akama , David Clive Blakemore , Robert Toms Jacobs , Peter Jones , David Christopher Limburg , Martins Sunday Oderinde , Matthew Alexander Perry , Jacob John Plattner , Rubben Federico Torella , Yasheen Zhou , Thean Yeow Yeoh
IPC: A61K31/69 , A61K31/519 , C07F5/02
Abstract: The present invention relates to boron containing compounds of Formula (I) X—Y—Z Formula (I) that inhibit phosphodiesterase 4 (PDE4). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating diseases, conditions, or disorders ameliorated by inhibition of PDE4.
-
公开(公告)号:US20230148402A1
公开(公告)日:2023-05-11
申请号:US18066468
申请日:2022-12-15
Applicant: Pfizer Inc.
Inventor: Tsutomu Akama , David Clive Blakemore , Robert Toms Jacobs , Peter Jones , David Christopher Limburg , Martins Sunday Oderinde , Matthew Alexander Perry , Jacob John Plattner , Joseph Walter Strohbach , Rubben Federico Torella , Thean Yeow Yeoh , Yasheen Zhou
IPC: A61K31/69 , A61K31/519 , C07F5/02
CPC classification number: A61K31/69 , A61K31/519 , C07F5/025 , C07B2200/13
Abstract: The present invention relates to boron containing compounds of Formula (I)
X—Y—Z Formula (I)
that inhibit phosphodiesterase 4 (PDE4). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating diseases, conditions, or disorders ameliorated by inhibition of PDE4.-
公开(公告)号:US20240124450A1
公开(公告)日:2024-04-18
申请号:US18466034
申请日:2023-09-13
Applicant: Pfizer Inc.
Inventor: Andrea Nicole Bootsma , David Christopher Ebner , Daniel Wei-Shung Kung , Matthew Alexander Perry , Daniel Copley Schmitt , Joseph Walter Strohbach , Atli Thorarensen
IPC: C07D471/04
CPC classification number: C07D471/04
Abstract: A compound of formula I having the structure:
or a pharmaceutically acceptable salt thereof, wherein A1 and A2 are independently O or S; X is selected from CH2, CD2, NR3, O, and S, where R3 is selected from hydrogen, C1-C4 linear or branched chain alkyl, halo(C1-C4)linear or branched chain alkyl, and hydroxyl(C1-C4)linear or branched chain alkyl; Y and Z are selected from C and N, where when Y is C, then Z is N, and when Y is N, then Z is C; R1 and R2 are independently selected from hydrogen, deuterium, C1-C4 linear or branched chain alkyl, etc.; or a C1-C2 alkyl substituted with a C3-C5 cycloalkyl ring; or taken together to form a C3-C6 cycloalkyl ring; or where X is CH2 or CD2, then R1 and R2 are independently selected from hydrogen, deuterium, halogen, hydroxyl, C1-C4 linear or branched chain alkyl, etc.; R4 is selected from hydrogen, deuterium, cyano, halogen, (C1-C3) alkoxy, etc.; R5 is selected from hydrogen, deuterium, halogen, C1-C3 alkoxy, amino, (C1-C4 linear or branched chain alkyl)amino, etc.; R6 is selected from hydrogen, deuterium, halogen, CO2R7 where R7 is selected from H and C1-C4 linear or branched chain alkyl, etc.; R8 is selected from hydrogen, deuterium, and C1-C3 linear or branched chain alkyl; R9 is selected from C1-C3 linear or branched chain alkyl, and a halo(C1-C3)linear or branched chain alkyl; and, n and m are independently selected from 0, 1 and 2. The invention also relates to pharmaceutical compositions thereof and therapeutic methods of use therewith.-
公开(公告)号:US11559538B2
公开(公告)日:2023-01-24
申请号:US17082102
申请日:2020-10-28
Applicant: Pfizer Inc.
Inventor: Joseph Walter Strohbach , Tsutomu Akama , David Clive Blakemore , Robert Toms Jacobs , Peter Jones , David Christopher Limburg , Martins Sunday Oderinde , Matthew Alexander Perry , Jacob John Plattner , Rubben Federico Torella , Yasheen Zhou , Thean Yeow Yeoh
IPC: C07F5/02 , A61K31/69 , A61K31/519
Abstract: The present invention relates to boron containing compounds of Formula (IA): that inhibit phosphodiesterase 4 (PDE4). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating diseases, conditions, or disorders ameliorated by inhibition of PDE4.
-
公开(公告)号:US10946031B2
公开(公告)日:2021-03-16
申请号:US16593171
申请日:2019-10-04
Applicant: Pfizer Inc.
IPC: C07F5/02 , A61K31/69 , A61K31/519
Abstract: The present invention relates to PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol including the crystalline monohydrate thereof.
-
-
-
-